Alterations of Bone Turnover and Bone Mass at Different Skeletal Sites due to Pure Glucocorticoid Excess: Study in Eumenorrheic Patients with Cushing's Syndrome
Open accessThe DOI matches its Crossref record.
Abstract
The aim of the present investigation was to study the effect of glucocorticoid excess on bone mass and turnover not influenced by other diseases known to affect skeleton and/or by different gonadal status and sex. We studied several markers of bone turnover and bone mineral density (BMD) by both quantitative computed tomography (at spine and forearm) and dual x-ray absorptiometry (at spine and three femoral sites) in 18 eugonadal female patients affected by Cushing's syndrome (CS) compared to 24 eugonadal healthy female subjects matched for age and body mass index. In CS patients, serum bone Gla protein, a marker of osteoblastic function, was reduced (3.28 +/- 2.3 vs. 6.47 +/- 2.5; P < 0.01), and bone resorption was increased, as indicated by increased urinary hydroxyproline (36.6 +/- 12 vs. 29.0 +/- 9.1, P < 0.05) and urinary deoxypyridinoline (22.1 +/- 8.0 vs. 16.4 +/- 6.3; P < 0.05). BMD was significantly (P < 0.05 or P < 0.01) reduced at all sites, except cortical forearm, in CS patients compared to controls. By comparing z-scores of reduced BMD in CS patients, spinal trabecular BMD was found to be the most severely affected. Furthermore, disease activity, as measured by urinary free cortisol, was significantly correlated with bone Gla protein (r = -0.57; P < 0.02), urinary hydroxyproline (r = 0.57; P < 0.02), urinary deoxypyridinoline (r = 0.48, P < 0.05), and BMD measured at spine and femur. Our results show that compared to matched control subjects, female eumenorrheic CS patients have reduced osteoblastic function, increased bone resorption, and reduced BMD, and that the severity of these abnormalities is statistically related to the severity of disease activity, as indicated by urinary free cortisol. Moreover, our data suggest a site and tissue specificity of the effect of glucocorticoid excess on bone mass.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Bone loss in inflammatory disorders
Hardy, R., & Cooper, M. S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0568 · Cited by 365
for the National Bone Health Alliance Bone Turnover Marker Project, Szulc, P., Naylor, K., Hoyle, N. R., Eastell, R., & Leary, E. T. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4082-4 · Cited by 327
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Chiodini, I., Morelli, V., Masserini, B., Salcuni, A. S., Eller-Vainicher, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Carnevale, V., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0468 · Cited by 168
Self-citationUtility of the trabecular bone score (TBS) in secondary osteoporosis
Ulivieri, F. M., Silva, B. C., Sardanelli, F., Hans, D., Bilezikian, J. P., & Caudarella, R. (2014) · Endocrine · doi:10.1007/s12020-014-0280-4 · Cited by 161
Glucocorticoid dose determines osteocyte cell fate
Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
“In addition, randomized controlled clinical trials have demonstrated that the stimulation of bone formation with human PTH 1–34 (hPTH[1–34]) can override the suppressive effects of glucocorticoids on bone formation and increase bone mass (16).”
BackgroundDiagnosis and complications of Cushing’s disease: gender-related differences
Zilio, M., Barbot, M., Ceccato, F., Camozzi, V., Bilora, F., Casonato, A., Frigo, A. C., Albiger, N., Daidone, V., Mazzai, L., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12299 · Cited by 93
Torlontano, M., Chiodini, I., Pileri, M., Guglielmi, G., Cammisa, M., Modoni, S., Carnevale, V., Trischitta, V., & Scillitani, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5856 · Cited by 91
Self-citationHeight, Bone Mineral Density and Bone Markers in Congenital Adrenal Hyperplasia
Paganini, C., Radetti, G., Livieri, C., Braga, V., Migliavacca, D., & Adami, S. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053253 · Cited by 87
Chiodini, I., Guglielmi, G., Battista, C., Carnevale, V., Torlontano, M., Cammisa, M., Trischitta, V., & Scillitani, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031413 · Cited by 82
“Thus, as trabecular bone tissue is noticeably affected by glucocorticoid excess (28), the QCT technique, although it appears to be more apt to accurately identify the effect of SH, confirms the results obtained with DXA in a small sample (12).”
ResultSelf-citationOsteoporosis Is More Prevalent in Adrenal than in Pituitary Cushing's Syndrome.
OHMORI, N., NOMURA, K., OHMORI, K., KATO, Y., ITOH, T., & TAKANO, K. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.1 · Cited by 81
Glucocorticoid‐induced osteoporosis: lessons from Cushing's syndrome
Tóth, M., & Grossman, A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12189 · Cited by 81
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism
Tauchmanovà, L., Pivonello, R., De Martino, M. C., Rusciano, A., De Leo, M., Ruosi, C., Mainolfi, C., Lombardi, G., Salvatore, M., & Colao, A. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0137 · Cited by 80
“In conclusion, this study confirms and extends previous observations on the negative effects of endogenous hypercortisolism on bone density, bone turnover, and fracture incidence (7, 8, 40 , 41).”
ResultTauchmanova, L., Rossi, R., Nuzzo, V, del Puente, A., Esposito-del Puente, A., Pizzi, C., Fonderico, F., Lupoli, G., & Lombardi, G. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450241 · Cited by 79
“Nevertheless, Chiodini et al. ( 6 ) found no correlation between BMD decrease at several skeletal sites, determined by DEXA, and estimated duration of active Cushing’s disease in 18 eumenorrhoic women.”
BackgroundInfluentialSkeletal involvement in adult patients with endogenous hypercortisolism
Chiodini, I., Torlontano, M., Carnevale, V., Trischitta, V., & Scillitani, A. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345601 · Cited by 78
Self-citationBone loss rate in adrenal incidentalomas: a longitudinal study
Chiodini, I., Torlontano, M., Carnevale, V., Guglielmi, G., Cammisa, M., Trischitta, V., & Scillitani, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8022 · Cited by 69
Self-citationFütő, L., Tőke, J., Patócs, A., Szappanos, Á., Varga, I., Gláz, E., Tulassay, Z., Rácz, K., & Tóth, M. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0514-x · Cited by 67
“Cortisol hypersecretion itself leads to increased bone resorption and, perhaps more importantly, to suppressed bone formation by its direct effect on osteoblasts [12], and it may also cause hypogonadotropic hypogonadism.”
BackgroundBone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma
Francucci, C. M., Pantanetti, P., Garrapa, G. G., Massi, F., Arnaldi, G., & Mantero, F. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01602.x · Cited by 65
“(Hermus et al., 1995; Chiodini et al., 1998; Dempster, 1998), our data, in agreement with some authors (Sartorio et al.”
ResultInfluentialHadjidakis, D., Tsagarakis, S., Roboti, C., Sfakianakis, M., Iconomidou, V., Raptis, S. A., & Thalassinos, N. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01676.x · Cited by 60
Osella, G., Reimondo, G., Peretti, P., Alì, A., Paccotti, P., Angeli, A., & Terzolo, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7178 · Cited by 54
The pituitary–adrenal axis and body composition
Fernandez-Rodriguez, E., Stewart, P. M., & Cooper, M. S. (2009) · Pituitary · doi:10.1007/s11102-008-0098-2 · Cited by 49
Kristo, C., Godang, K., Ueland, T., Lien, E., Aukrust, P., Froland, S., & Bollerslev, J. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460389 · Cited by 45
“Secondary osteoporosis is a major problem in several endocrine and chronic inflammatory disorders, but the pathogenic mechanisms have been only partly elucidated (1 ‐ 3). Among others, we have recently shown that bone mass as well as bone area are reduced in endogenous Cushing’s syndrome (CS), most probably related to…”
BackgroundPrevention of glucocorticoid induced bone changes with beta-ecdysone
Dai, W., Jiang, L., Lay, Y.-A. E., Chen, H., Jin, G., Zhang, H., Kot, A., Ritchie, R. O., Lane, N. E., & Yao, W. (2015) · Bone · doi:10.1016/j.bone.2015.01.001 · Cited by 30
Kahl, K. G., Rudolf, S., Dibbelt, L., Stoeckelhuber, B. M., Gehl, H.-B., Hohagen, F., & Schweiger, U. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1711-5 · Cited by 27
Metadata
- Authors
- Chiodini, I.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-06-01
- Volume
- 83
- Issue
- 6
- Pages
- 1863-1867
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2104880420
- Cited by
- 153
- References
- 0
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.